Rathbones Group PLC Exelixis, Inc. Transaction History

Rathbones Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$17.44 - $23.16 $336,592 - $446,988	-19,300 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$16.3 - $21.14 $13,040 - $16,912	800 Added 4.32%	19,300 $408,000
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $20,530 - $25,220	1,000 Added 5.71%	18,500 $418,000
Q3 2018 Oct 12, 2018	BUY	$15.87 - $22.4 $15,870 - $22,400	1,000 Added 6.06%	17,500 $310,000
Q1 2018 Apr 06, 2018	BUY	$22.15 - $31.89 $22,150 - $31,890	1,000 Added 6.45%	16,500 $365,000
Q4 2017 Jan 24, 2018	BUY	$24.23 - $30.93 $24,230 - $30,930	1,000 Added 6.9%	15,500 $471,000
Q3 2017 Oct 24, 2017	BUY	$23.35 - $29.24 $338,575 - $423,980	14,500	14,500 $351,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

Stay updated on Rathbones Group PLC with notifications on news.